First-in-class drug approvals vs Autoimmune cell therapy and T-cell engager trial starts in China

In 2025, first-in-class drug approvals in China stood at 11, against 76 for autoimmune cell therapy and T-cell engager trial starts.

Change the pair

The series

Over time

China, spaced by time. Both series are in count, so they share one axis; the legend names each line.

First-in-class drug approvals and Autoimmune cell therapy and T-cell engager trial starts

Unit: count · 10 observations

2 series · one axis

View the underlying data

First-in-class drug approvals and Autoimmune cell therapy and T-cell engager trial starts: China
Indicator	Period	Type	Value
First-in-class drug approvals	2025	Actual	11
First-in-class drug approvals	2024	Actual	48
First-in-class drug approvals	2023	Actual	40
First-in-class drug approvals	2022	Actual	21
Autoimmune cell therapy and T-cell engager trial starts	2025	Actual	76
Autoimmune cell therapy and T-cell engager trial starts	2024	Actual	51
Autoimmune cell therapy and T-cell engager trial starts	2023	Actual	9
Autoimmune cell therapy and T-cell engager trial starts	2022	Actual	3
Autoimmune cell therapy and T-cell engager trial starts	2021	Actual	6
Autoimmune cell therapy and T-cell engager trial starts	2020	Actual	1

Source: NMPA, NHSA, ClinicalTrials.gov · CC BY 4.0 · First-in-class drug approvals · Autoimmune cell therapy and T-cell engager trial starts

Shared periods

Side by side

4 periods are published for both series in China as annual figures on the same basis. Comparing anything else would mean comparing different periods.

Period	First-in-class drug approvals	Autoimmune cell therapy and T-cell engager trial starts
2022	21 NMPA	3 ClinicalTrials.gov
2023	40 NMPA	9 ClinicalTrials.gov
2024	48 NMPA	51 ClinicalTrials.gov
2025	11 NHSA	76 ClinicalTrials.gov

Provenance

Where these numbers come from